HALIFAX, Feb. 13 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, today announced that the Company's Board of Directors has elected
Dr. James Smith as Chairman. Mr. Romano Robusto was elected as a Director at
MedMira's 2009 Annual General Meeting held on January 30, 2009.
A member of MedMira's Board of Directors since 2000, Dr. Smith has served
on the Board's Audit and Compensation committees. He also served as the
Company's Vice President of Corporate Affairs and will be stepping down from
this position to focus on his duties as Chairman.
"I was attracted to MedMira because of the innovative diagnostic products
being developed by a Nova Scotia company. I saw the value of the Company's
rapid tests as public health tools in fighting global healthcare challenges
like HIV and Hepatitis and wanted to be a part of it," said Dr. Smith,
Chairman of the Board. "In my new role I look forward to helping the MedMira
team continue to expand into global markets, gain valuable strategic partners,
and build shareholder value."
Prior to joining MedMira, Dr. Smith was a member of the Nova Scotia
Legislature for 19 years, serving in various roles including Minister of
Health. Born and raised in Nova Scotia, Dr. Smith received a BSc from the
University of British Columbia and his medical degree from Dalhousie
University. Dr. Smith practiced family medicine in Nova Scotia for 29 years,
prior to entering political life. Active in the community, Dr. Smith also
serves on The Board of Directors' of BioNova, the Nova Scotia Biotechnology
and Life Sciences Industry Association, the Alzheimer Society of Nova Scotia;
the NovaKnowledge Advisory Council and the Advisory Board (Atlantic) Ballet
Mr. Romano Robusto is a seasoned life sciences executive with over 20
years of experience in the industry, primarily in the diagnostic sector. He
has held a broad range of positions including Intellectual Property, Sales,
Business Development, Strategic Planning and Senior Management. Mr. Robusto
most recently served as the Interim Chief Executive Officer of Radient
Technologies and prior to this he worked within the life sciences division of
the SGF, the economic development arm of the Quebec Government, responsible
for investing development capital into companies that had achieved commercial
viability. Mr. Robusto has also held numerous positions within the diagnostic
division of Biochem Pharma. He holds degrees in Common and Civil law from
McGill University, a BSc in Physical Therapy from McGill University and
majored in Biochemistry at Concordia University.
"On behalf of the Board and the Company I congratulate Dr. Smith on his
new role as Chairman and welcome Mr. Robusto," said Hermes Chan, president and
CEO, MedMira Inc. "Dr. Smith has been key member of MedMira's leadership team
and we look forward to his continued guidance and perspective as Chairman.
Additionally Mr. Robusto's life science industry experience and insight will
be valuable in helping MedMira move forward successfully," said Hermes Chan,
president and CEO, MedMira Inc.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information:
For further information: Andrea Young, Corporate Communications, MedMira
(902) 450-1588, email@example.com